Investors

Press Releases

Press Releases

May 03, 2021
Data provide further evidence for the central role of IRAK4 in inflammation in hidradenitis suppurativa and support both the degrader rationale for targeting IRAK4 and KT-474 development KT-474 is in Phase 1 clinical development as a first-in-class oral IRAK4 degrader for the treatment of
Apr 09, 2021
WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring new
Displaying 21 - 30 of 32